Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

rigel pharmaceutical - RIGL

RIGL

Close Chg Chg %
44.50 -3.66 -8.22%

Closed Market

40.84

-3.66 (8.22%)

Volume: 694.35K

Last Updated:

Jan 9, 2026, 4:00 PM EDT

Trade Now

Company Overview: rigel pharmaceutical - RIGL

RIGL Key Data

Open

$44.92

 Day Range

40.75 - 45.25

52 Week Range

15.50 - 52.06

 Market Cap

$853.66M

Shares Outstanding

18.15M

 Public Float

17.68M

Beta

1.11

 Rev. Per Employee

N/A

P/E Ratio

7.02

 EPS

$6.34

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

552.10K

  

RIGL Performance

1 Week
 
 -2.37%
 
1 Month
 
 0.15%
 
3 Months
 
 44.93%
 
1 Year
 
 151.32%
 
5 Years
 
 14.08%
 

RIGL Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 5
Full Ratings ➔

About rigel pharmaceutical - RIGL

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

RIGL At a Glance

Rigel Pharmaceuticals, Inc.
611 Gateway Boulevard
South San Francisco, California 94080-1985
Phone 1-650-624-1100 Revenue 179.28M
Industry Pharmaceuticals: Major Net Income 17.49M
Sector Health Technology 2024 Sales Growth 53.384%
Fiscal Year-end 12 / 2025 Employees 164
View SEC Filings

RIGL Valuation

P/E Current 7.019
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 17.014
Price to Sales Ratio 1.659
Price to Book Ratio 90.596
Price to Cash Flow Ratio 9.45
Enterprise Value to EBITDA 10.603
Enterprise Value to Sales 1.563
Total Debt to Enterprise Value 0.214

RIGL Efficiency

Revenue/Employee 1,093,158.537
Income Per Employee 106,615.854
Receivables Turnover 4.308
Total Asset Turnover 0.587

RIGL Liquidity

Current Ratio 2.134
Quick Ratio 1.98
Cash Ratio 1.222

RIGL Profitability

Gross Margin 89.599
Operating Margin 13.494
Pretax Margin 10.244
Net Margin 9.753
Return on Assets 5.729
Return on Equity N/A
Return on Total Capital 27.643
Return on Invested Capital 43.872

RIGL Capital Structure

Total Debt to Total Equity 1,823.753
Total Debt to Total Capital 94.802
Total Debt to Total Assets 12.158
Long-Term Debt to Equity 1,593.917
Long-Term Debt to Total Capital 82.855
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Rigel Pharmaceutical - RIGL

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
149.24M 120.24M 116.88M 179.28M
Sales Growth
+37.39% -19.43% -2.79% +53.38%
Cost of Goods Sold (COGS) incl D&A
1.66M 1.75M 7.11M 18.65M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
1.16M 998.00K 1.24M 2.23M
Depreciation
1.16M 898.00K 200.00K 100.00K
Amortization of Intangibles
- 100.00K 1.04M 2.13M
COGS Growth
+85.92% +5.11% +306.52% +162.26%
Gross Income
147.57M 118.49M 109.77M 160.63M
Gross Income Growth
+36.99% -19.70% -7.36% +46.33%
Gross Profit Margin
+98.88% +98.55% +93.92% +89.60%
2021 2022 2023 2024 5-year trend
SG&A Expense
156.55M 173.28M 130.26M 136.44M
Research & Development
65.24M 60.27M 24.52M 23.38M
Other SG&A
91.31M 113.01M 105.74M 113.06M
SGA Growth
+14.52% +10.69% -24.83% +4.74%
Other Operating Expense
- - - (557.00K)
-
Unusual Expense
- - 3.52M 1.32M
-
EBIT after Unusual Expense
(12.50M) (55.55M) (20.49M) 24.19M
Non Operating Income/Expense
47.00K 684.00K 2.27M 2.09M
Non-Operating Interest Income
47.00K 684.00K 2.27M 2.09M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
4.86M 3.71M 6.87M 7.92M
Interest Expense Growth
+259.20% -23.72% +85.38% +15.22%
Gross Interest Expense
4.86M 3.71M 6.87M 7.92M
Interest Capitalized
- - - -
-
Pretax Income
(17.31M) (58.57M) (25.09M) 18.37M
Pretax Income Growth
+41.81% -238.40% +57.16% +173.20%
Pretax Margin
-11.60% -48.71% -21.47% +10.24%
Income Tax
- - 605.00K 881.00K
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(17.91M) (58.57M) (25.09M) 17.48M
Minority Interest Expense
- - - -
-
Net Income
(17.91M) (58.57M) (25.09M) 17.48M
Net Income Growth
+39.77% -226.97% +57.16% +169.69%
Net Margin Growth
-12.00% -48.71% -21.47% +9.75%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(17.91M) (58.57M) (25.09M) 17.48M
Preferred Dividends
- - - -
-
Net Income Available to Common
(17.91M) (58.57M) (25.09M) 17.48M
EPS (Basic)
-1.0507 -3.3974 -1.4419 0.9946
EPS (Basic) Growth
+40.39% -223.35% +57.56% +168.98%
Basic Shares Outstanding
17.05M 17.24M 17.40M 17.58M
EPS (Diluted)
-1.0507 -3.3974 -1.4419 0.9886
EPS (Diluted) Growth
+40.39% -223.35% +57.56% +168.56%
Diluted Shares Outstanding
17.05M 17.24M 17.40M 17.69M
EBITDA
(7.81M) (53.23M) (19.25M) 26.42M
EBITDA Growth
+72.36% -581.33% +63.83% +237.23%
EBITDA Margin
-5.24% -44.27% -16.47% +14.74%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 49.60
Number of Ratings 5 Current Quarters Estimate 0.695
FY Report Date 03 / 2026 Current Year's Estimate 4.171
Last Quarter’s Earnings 1.02 Median PE on CY Estimate N/A
Year Ago Earnings 6.472 Next Fiscal Year Estimate 4.958
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 2 2 5 5
Mean Estimate 0.70 0.99 4.17 4.96
High Estimates 0.70 1.08 5.19 7.13
Low Estimate 0.69 0.90 3.58 2.94
Coefficient of Variance 1.02 12.86 16.70 34.58

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 3 3 2
OVERWEIGHT 0 0 0
HOLD 2 2 3
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Rigel Pharmaceutical - RIGL

Date Name Shares Transaction Value
Mar 21, 2025 Raul R. Rodriguez CEO, President; Director 26,250 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 21, 2025 Raul R. Rodriguez CEO, President; Director 30,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 21, 2025 Dean L. Schorno EVP & Chief Financial Officer 5,625 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 21, 2025 Dean L. Schorno EVP & Chief Financial Officer 7,850 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 21, 2025 Raymond J. Furey EVP, GC, CCO & Corp Sec 9,375 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 21, 2025 Raymond J. Furey EVP, GC, CCO & Corp Sec 7,850 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 21, 2025 Lisa Rojkjaer EVP, Chief Medical Officer 9,375 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 21, 2025 David A. Santos EVP, Chief Commercial Officer 6,875 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 21, 2025 David A. Santos EVP, Chief Commercial Officer 7,850 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 11, 2025 Mark J. Frohlich Director 12,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Rigel Pharmaceutical in the News